Patients With Neurological Diseases Like Parkinson's Disease May Also be Suffering From a Secondary Condition They Didn't Know Existed, New Survey Shows
09 févr. 2012 08h30 HE
|
Chelsea Therapeutics
CHARLOTTE, N.C., Feb. 9, 2012 (GLOBE NEWSWIRE) -- Patients with neurological diseases, such as Parkinson's disease and multiple system atrophy (MSA), may be experiencing symptoms associated with the...
Chelsea Therapeutics Joins With Advocates, Patients and Experts to Raise Awareness of Neurogenic Orthostatic Hypotension (NOH)
26 janv. 2012 08h45 HE
|
Chelsea Therapeutics
CHARLOTTE, N.C., Jan. 26, 2012 (GLOBE NEWSWIRE) -- Patients with Parkinson's disease, multiple system atrophy (MSA) and other neurological disorders can be greatly affected by the symptoms of their...
Chelsea Therapeutics Announces Exercise of Over-Allotment Option and Completion of the Public Offering of Common Stock
11 janv. 2012 09h25 HE
|
Chelsea Therapeutics
CHARLOTTE, N.C., Jan. 11, 2012 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) has completed its previously announced underwritten public offering of 4,989,275 shares of...
Chelsea Therapeutics Prices Public Offering of Common Stock
06 janv. 2012 08h45 HE
|
Chelsea Therapeutics
CHARLOTTE, N.C., Jan. 6, 2012 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced today that it has priced an underwritten public offering of 4,338,500 shares of its...
Chelsea Therapeutics Announces Proposed Public Offering of Common Stock
05 janv. 2012 16h03 HE
|
Chelsea Therapeutics
CHARLOTTE, N.C., Jan. 5, 2012 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced today its intention to offer, subject to market and other conditions, $20.0 million...
Chelsea Therapeutics Announces FDA Advisory Committee Meeting Date for Review of NORTHERA(TM) NDA for the Treatment of Symptomatic NOH
03 janv. 2012 07h30 HE
|
Chelsea Therapeutics
CHARLOTTE, N.C., Jan. 3, 2012 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced that the U.S. Food and Drug Administration (FDA) has scheduled a meeting of the...
Chelsea Therapeutics Reports Topline Results From Phase II Trial of Droxidopa in Fibromyalgia
22 déc. 2011 07h30 HE
|
Chelsea Therapeutics
CHARLOTTE, N.C., Dec. 22, 2011 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced results of a Phase II dose-finding study designed to evaluate the safety and...
Chelsea Therapeutics Receives Notice of Allowance of Key U.S. Patent for Novel, Controlled Release Formulation of Northera(TM)
15 déc. 2011 07h30 HE
|
Chelsea Therapeutics
CHARLOTTE, N.C., Dec. 15, 2011 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) received a notice of allowance from the U.S. Patent & Trademark Office (USPTO) for its...
Chelsea Therapeutics to Present at the Piper Jaffray 23rd Annual Healthcare Conference
29 nov. 2011 07h30 HE
|
Chelsea Therapeutics
CHARLOTTE, N.C., Nov. 29, 2011 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) is scheduled to present at the Piper Jaffray 23rd Annual Healthcare Conference at 11:30 AM ET...
Chelsea Therapeutics Announces FDA Acceptance of NDA for Filing and Designation of Priority Review of NORTHERA(TM) for the Treatment of Symptomatic NOH
17 nov. 2011 07h30 HE
|
Chelsea Therapeutics
CHARLOTTE, N.C., Nov. 17, 2011 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the New...